Curis (NASDAQ:CRIS – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Price Performance
Shares of CRIS opened at $3.02 on Tuesday. The firm has a 50-day moving average of $3.30 and a 200-day moving average of $4.28. The company has a market cap of $25.57 million, a PE ratio of -0.39 and a beta of 3.41. Curis has a one year low of $2.86 and a one year high of $17.49.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Curis in a research note on Tuesday, December 10th.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than Curis
- 3 Warren Buffett Stocks to Buy Now
- Confluent: How Data Streaming May Transform AI
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Which Wall Street Analysts are the Most Accurate?
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
